NLS Pharmaceutics Ltd is a biotechnology business based in the US. NLS Pharmaceutics Ltd shares (NLSP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.43 – an increase of 9.58% over the previous week.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.43 |
|---|---|
| 52-week range | $3.00 - $29.08 |
| 50-day moving average | $4.59 |
| 200-day moving average | $7.43 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-6.74 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.43 from 2024-11-22
| 1 week (2024-11-15) | 9.58% |
|---|---|
| 1 month (2024-10-25) | -17.94% |
| 3 months (2024-08-23) | 1,857.76% |
| 6 months (2024-05-24) | 1,871.26% |
| 1 year (2023-11-24) | 757.07% |
|---|---|
| 2 years (2022-11-23) | -88.09% |
| 3 years (2021-11-24) | 70.8 |
| 5 years (2019-11-21) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -227.76% |
| Return on equity TTM | -862.92% |
| Profit margin | 0% |
| Book value | $-9.40 |
| Market Capitalization | $12.8 million |
TTM: trailing 12 months
We're not expecting NLS Pharmaceutics Ltd to pay a dividend over the next 12 months.
You may also wish to consider:
NLS Pharmaceutics Ltd's shares were split on a 1:40 basis on 26 September 2024 . So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NLS Pharmaceutics Ltd shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for NLS Pharmaceutics Ltd shares which in turn could have impacted NLS Pharmaceutics Ltd's share price.
Over the last 12 months, NLS Pharmaceutics Ltd's shares have ranged in value from as little as $3 up to $29.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NLS Pharmaceutics Ltd's is -0.522. This would suggest that NLS Pharmaceutics Ltd's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, NLS Pharmaceutics Ltd has bucked the trend.
To put NLS Pharmaceutics Ltd's beta into context you can compare it against those of similar companies.
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S. A. for commercialization and distribution of Nolazol in Latin America.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.